Today it was reported that the CSO of Agios Pharma (AGIO), Scott Biller, exercised options to buy 7,218 AGIO shares at $2.33 a share, for a total transaction value of $16.82K.
Following this transaction Scott Biller’s holding in the company was increased by 9.07% to a total of $4.23 million. Following Scott Biller’s last AGIO Buy transaction on December 26, 2018, the stock climbed by 3.8%.
See today’s analyst top recommended stocks >>
Based on Agios Pharma’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $30.23 million and GAAP net loss of $93.08 million. In comparison, last year the company earned revenue of $8.76 million and had a GAAP net loss of $90.83 million. Currently, Agios Pharma has an average volume of 431.8K.
Based on 5 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $76.67, reflecting a 54.7% upside. Three different firms, including Cowen & Co. and Piper Jaffray, currently also have a Buy rating on the stock.
Scott Biller’s trades have generated a -20.7% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
